All In Biotech

Drug Trial Radar · NCT00152386

A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis

A Phase III Multicentre, Double Blind, Placebo-controlled, Parallel Group 52-week Study to Assess the Efficacy and Safety of 2 Dose Regimens of Lyophilised CDP870 as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate

Last checked: Nov 20, 2026Latest source record: Dec 1, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 950 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

950

Actual

Start

Feb 2005

Primary completion

Oct 2006

Study completion Oct 2006

Sponsor

Lead sponsor
UCB PharmaUCB
Sponsor type
Industry
First posted
Sep 9, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients will be assigned to one of three treatment groups. Study medication is administered over a 52 week study duration.

Conditions

  • Rheumatoid Arthritis

Interventions

  • Certolizumab pegol (CDP870)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the efficacy of CDP870 in combination with Methotrexate in the treatment of Rheumatoid Arthritis and prevention of structural damage by measuring the ACR20 response at week 24 and change from Baseline

Locations

76 sites in 13 countries. Site status is shown where the registry gives one.

  • Site not named

    Huntsville, Alabama

  • Site not named

    Paradise Valley, Arizona

  • Site not named

    La Jolla, California

  • Site not named

    San Diego, California

  • Site not named

    Denver, Colorado

  • Site not named

    Danbury, Connecticut

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Aventura, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Coeur d'Alene, Idaho

  • Site not named

    Springfield, Illinois

  • Site not named

    Wichita, Kansas

  • Site not named

    Wheaton, Maryland

  • Site not named

    St Louis, Missouri

  • Site not named

    Lincoln, Nebraska

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Cleveland, Ohio

  • Site not named

    Dayton, Ohio

  • Site not named

    Duncansville, Pennsylvania

  • Site not named

    Charleston, South Carolina

  • Site not named

    Austin, Texas

  • Site not named

    Dallas, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Capital Federal, Argentina

  • Site not named

    Córdoba, Argentina

  • Site not named

    Camperdown, Australia

  • Site not named

    Coffs Harbour, Australia

  • Site not named

    Cotton Tree, Australia

  • Site not named

    Malvern, Australia

  • Site not named

    Shenton Park, Australia

  • Site not named

    Victoria Park, Australia

  • Site not named

    Westmead, Australia

  • Site not named

    Wooloongabba, Australia

  • Site not named

    Antwerp, Belgium

  • Site not named

    Brussels, Belgium

  • Site not named

    Liège, Belgium

  • Site not named

    Merksem, Belgium

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.